

## Special Issue

# Personalized Diagnostics, Treatment, and Outcomes of Chronic Kidney Diseases

### Message from the Guest Editor

Chronic kidney disease is one of the most potent risk factors for end-stage kidney disease. The number of patients with chronic kidney disease is increasing. Although several new drugs have been launched in clinical practice, the global need for optimal strategies to prevent the progression of chronic kidney disease urgently needs to be addressed. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the science and present the latest findings in the field of chronic kidney disease. We call for research that explores all conditions associated with chronic kidney disease, using basic science, clinical- and population-based approaches, and all kinds of actions for public awareness. Scientific advancements in the field of chronic kidney disease promise a brighter future for patients.

---

### Guest Editor

Prof. Dr. Haruhito A. Uchida

Department of Chronic Kidney Disease and Cardiovascular Disease,  
Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama  
University, Okayama, Japan

---

### Deadline for manuscript submissions

closed (30 June 2024)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/173756](https://mdpi.com/si/173756)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2024).